Home > Boards > US Listed > Medical - Equipment > Edwards Life Sciences LLC (EW)

Edwards Lifesciences Corp (NYSE:EW) reported Q4 adjusted EPS

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
THESTCOKHUNTER Member Profile
 
Followed By 2
Posts 482
Boards Moderated 0
Alias Born 12/17/11
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/15/2019 4:54:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/10/2019 5:03:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/10/2019 5:03:02 PM
Edwards Lifesciences To Host Earnings Conference Call On July 23, 2019 PR Newswire (US) - 7/9/2019 10:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/8/2019 2:26:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 6:13:47 PM
Edwards Comments On Updated TAVR National Coverage Determination PR Newswire (US) - 6/21/2019 6:18:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/14/2019 6:00:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/14/2019 6:00:42 PM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/14/2019 5:24:44 PM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/14/2019 5:23:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 6:00:57 PM
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire (US) - 6/4/2019 11:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 4:52:57 PM
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation PR Newswire (US) - 6/3/2019 4:15:00 PM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 4:02:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/30/2019 6:16:36 PM
Edwards Announces Milestones For Transcatheter Mitral Program PR Newswire (US) - 5/22/2019 2:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 6:00:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 6:58:22 PM
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020 PR Newswire (US) - 5/15/2019 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 7:37:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 7:05:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 7:01:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2019 6:40:22 PM
THESTCOKHUNTER   Sunday, 02/05/12 09:17:37 AM
Re: DrMG post# 226
Post # of 276 
Edwards Lifesciences Corp (NYSE:EW) reported Q4 adjusted EPS of 62c, compared with analysts’ consensus estimate of 59c. The adjusted EPS excludes several items, including a pre-tax $17.6M special charge related to southern European receivables risk, a global realignment charge and a legal settlement. The company’s revenue came in lower than expected. Moreover, Edwards provided Q1 adjusted EPS guidance of 47c-49c, versus the consensus estimate of 55c, and the company expects its Q1 revenue to also come in lower than expected. Edwards’ Q1 EPS guidance excludes several special items, the company said. Edwards reiterated its 2012 EPS guidance of $2.70-$2.80, excluding special items, as well as its 2012 transcatheter heart valve sales guidance of $560M-$630M. Edwards’ guidance assumes a mid-year 2012 approval of Cohort A of the Partner Trial of its Sapien heart valve, the company said. “We have just begun offering our life saving Sapien technology to many inoperable U.S. patients suffering from severe aortic stenosis and also anticipate making it available for patients whose conditions place them at high risk for surgery,” said Edwards CEO Michael Mussallem. In a note to investors, Jefferies recommended buying the stock on weakness today, as the firm believes that the company’s outlook is largely unchanged following the results. Jefferies maintains a positive bias and Buy rating on the stock. In late morning trading, Edward dropped $9.36, or 11.60%, to $71.31.
The shares closed at $71.54, down $9.13, or 11.32%, on the day. Its market capitalization is $8.16 billion.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist